OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 601–700 of 1,030
Cellular Interactions in Lymph Node Development
Cupedo, T., & Mebius, R. E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.21 · Cited by 138
Gonzalez-Suarez, E., Branstetter, D., Armstrong, A., Dinh, H., Blumberg, H., & Dougall, W. C. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01298-06 · Cited by 129
“The tumor necrosis factor (TNF) family member RANKL and its receptor RANK are key regulators of osteoclast differentiation and activation (16, 30).”
BackgroundHiasa, M., Abe, M., Nakano, A., Oda, A., Amou, H., Kido, S., Takeuchi, K., Kagawa, K., Yata, K., Hashimoto, T., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215020 · Cited by 124
Xiong, J., Piemontese, M., Thostenson, J. D., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2014) · Bone · doi:10.1016/j.bone.2014.06.006 · Cited by 127
“Moreover, since T lymphocytes express RANKL (6), RANKL produced by these cells may also contribute to PTH-induced bone loss.”
BackgroundFunctional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines
Fiumara, P. F., Snell, V., Li, Y., Mukhopadhyay, A., Younes, M., Gillenwater, A. M., Cabanillas, F., Aggarwal, B. B., & Younes, A. (2001) · Blood · doi:10.1182/blood.v98.9.2784 · Cited by 155
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology
Zauli, G., & Secchiero, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.002 · Cited by 141
Estrogens in rheumatoid arthritis; the immune system and bone
Islander, U., Jochéms, C., Lagerquist, M. K., Forsblad‐d’Elia, H., & Carlsten, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.05.018 · Cited by 148
Murine and Chicken Chondrocytes Regulate Osteoclastogenesis by Producing RANKL in Response to BMP2
Usui, M., Xing, L., Drissi, H., Zuscik, M., O'Keefe, R., Chen, D., & Boyce, B. F. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071025 · Cited by 128
Multiple myeloma biology: lessons from the 5TMM models
Vanderkerken, K., Asosingh, K., Croucher, P., & Van Camp, B. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00035.x · Cited by 122
“The receptor of NF-kB ligand (RANKL) has been shown to play a critical role in the normal osteoclast development (51).”
BackgroundSchlöndorff, J., Lum, L., & Blobel, C. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010741200 · Cited by 130
Catalytic Properties of ADAM19
Chesneau, V., Becherer, J. D., Zheng, Y., Erdjument-Bromage, H., Tempst, P., & Blobel, C. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302781200 · Cited by 129
Advances in Defining Regulators of Cementum Development and Periodontal Regeneration
Foster, B. L., Popowics, T. E., Fong, H. K., & Somerman, M. J. (2007) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)78003-6 · Cited by 134
HOU, G.-Q., GUO, C., SONG, G.-H., FANG, N., FAN, W.-J., CHEN, X.-D., YUAN, L., & WANG, Z.-Q. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1406 · Cited by 122
“Mice deficient in RANKL or RANK genes exhibit severe osteopetrosis as they do not form osteoclasts (29-32).”
BackgroundMechanisms involved in normal and pathological osteoclastogenesis
Park‐Min, K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2817-9 · Cited by 133
“The functions of RANK/RANKL have been clearly demonstrated by RANKL or RANKdeficient mice [11, 16, 17].”
Molecular Mechanism of the Bifunctional Role of Lipopolysaccharide in Osteoclastogenesis
Liu, J., Wang, S., Zhang, P., Said-Al-Naief, N., Michalek, S. M., & Feng, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809789200 · Cited by 126
Peng, S., Liu, X. S., Huang, S., Li, Z., Pan, H., Zhen, W., Luk, K. D. K., Guo, X.-D. E., & Lu, W. W. (2011) · Bone · doi:10.1016/j.bone.2011.08.031 · Cited by 133
“Genetic ablation of RANKL resulted in osteopetrosis phenotype associated with a lack of osteoclasts [28].”
BackgroundResultVan Wesenbeeck, L., Odgren, P. R., MacKay, C. A., D'Angelo, M., Safadi, F. F., Popoff, S. N., Van Hul, W., & Marks, S. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202332999 · Cited by 123
Origin, development, and homeostasis of tissue‐resident macrophages
Haldar, M., & MURPHY, K. M. M. (2014) · Immunological Reviews · doi:10.1111/imr.12215 · Cited by 142
Harper, E., Forde, H. E., Davenport, C., Rochfort, K. D., Smith, D., & Cummins, P. M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.02.003 · Cited by 133
Yasui, T., Hirose, J., Tsutsumi, S., Nakamura, K., Aburatani, H., & Tanaka, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.464 · Cited by 126
“RANKL was identified originally as a T-lymphocyte-derived factor that is involved in dendritic cell survival, and subsequent studies revealed that it has an essential role in osteoclastogenesis.((7)) RANKL is a member of the tumor necrosis factor a (TNF-a) superfamily, and the binding of RANKL to its receptor RANK, a…”
BackgroundRANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 142
McCauley, L. K., & Nohutcu, R. M. (2002) · Journal of Periodontology · doi:10.1902/jop.2002.73.11.1377 · Cited by 121
Sims, N. A. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.003 · Cited by 128
Anastasilakis, A. D., Pοlyzos, S. A., & Makras, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0056 · Cited by 131
Osteoprotegerin: a link between osteoporosis and arterial calcification?
Hofbauer, L. C., & Schoppet, M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05494-0 · Cited by 133
Onyia, J. E., Miles, R. R., Yang, X., Halladay, D. L., Hale, J., Glasebrook, A., McClure, D., Seno, G., Churgay, L., Chandrasekhar, S., et al. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.5.863 · Cited by 127
Nagasawa, T., Kiji, M., Yashiro, R., Hormdee, D., Lu, H., Kunze, M., Suda, T., Koshy, G., Kobayashi, H., Oda, S., et al. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00185.x · Cited by 151
Influence of Glucocorticoids on Human Osteoclast Generation and Activity
Sivagurunathan, S., Muir, M. M., Brennan, T. C., Seale, J. P., & Mason, R. S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041233 · Cited by 126
Parathyroid Hormone-induced Bone Resorption Does Not Occur in the Absence of Osteopontin
Ihara, H., Denhardt, D. T., Furuya, K., Yamashita, T., Muguruma, Y., Tsuji, K., Hruska, K. A., Higashio, K., Enomoto, S., Nifuji, A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010938200 · Cited by 122
Yamada, T., Yamazaki, H., Yamane, T., Yoshino, M., Okuyama, H., Tsuneto, M., Kurino, T., Hayashi, S.-I., & Sakano, S. (2003) · Blood · doi:10.1182/blood-2002-06-1740 · Cited by 124
Piemontese, M., Onal, M., Xiong, J., Han, L., Thostenson, J. D., Almeida, M., & O’Brien, C. A. (2016) · Scientific Reports · doi:10.1038/srep24262 · Cited by 119
New Insights Into Osteoclast Biology
McDonald, M. M., Kim, A. S., Mulholland, B. S., & Rauner, M. (2021) · JBMR Plus · doi:10.1002/jbm4.10539 · Cited by 133
Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease
Boyce, B. F., Schwarz, E. M., & Xing, L. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000231913.32364.32 · Cited by 122
Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease
Ziegler, S., Kudlacek, S., Luger, A., & Minar, E. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.042 · Cited by 131
“Osteoprotegerin (OPG) is a secretory glycoprotein that elongs to the tumor necrosis factor receptor family and nhibits receptor activator of nuclear factor-kappa B ligand RANKL)-mediated osteoclastic bone resorption in vitro and n vivo [1–4].”
BackgroundOsteoclast fusion and regulation by RANKL-dependent and independent factors
Xing, L., Xiu, Y., & Boyce, B. F. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i12.212 · Cited by 131
Trial Watch: Immunostimulatory cytokines
Vacchelli, E., Galluzzi, L., Eggermont, A., Galon, J., Tartour, E., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 119
Piemontese, M., Xiong, J., Fujiwara, Y., Thostenson, J. D., & O'Brien, C. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00219.2016 · Cited by 119
The molecular mechanism of osteoclastogenesis in rheumatoid arthritis.
Udagawa, N., Kotake, S., Kamatani, N., Takahashi, N., & Suda, T. (2002) · Arthritis Research · doi:10.1186/ar431 · Cited by 138
Modulation of osteoclast formation
Quinn, J. M. W., & Gillespie, M. T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.076 · Cited by 142
Page, G., & Miossec, P. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21211 · Cited by 121
Cytokines in rheumatoid arthritis
Vervoordeldonk, M. J., & Tak, P. P. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0067-0 · Cited by 137
Eph Receptors and Ephrin Signaling Pathways: A Role in Bone Homeostasis
Edwards, C. M., & Mundy, G. R. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.263 · Cited by 122
“activation of the receptor activator of nuclear factor κB (RANK) on the surface of the precursor cells, by its ligand, RANKL, which is expressed by bone marrow stromal cells and osteoblasts [61-65].”
BackgroundEBF2 Regulates Osteoblast-Dependent Differentiation of Osteoclasts
Kieslinger, M., Roessler, S. K., Dobreva, G. D., Dorn, T., Croci, L., Erben, R. G., Consalez, G. G., & Grosschedl, R. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.10.009 · Cited by 135
“In addition, the tumor necrosis factor-related receptor activator of NF-kB ligand (RANKL), which is displayed on the cell surface of preosteoblasts and osteoblasts, regulates the differentiation of preosteoclasts by the interaction with the receptor activator of NF-kB (RANK) (Dougall et al., 1999; Kong et al., 1999; L…”
Gaffen, S. L. (2004) · Arthritis Research · doi:10.1186/ar1444 · Cited by 131
“RANKL is a member of the TNF receptor superfamily and is central in controlling osteoclastogenesis, and hence bone degradation [46,47].”
BackgroundKaneda, T., Nojima, T., Nakagawa, M., Ogasawara, A., Kaneko, H., Sato, T., Mano, H., Kumegawa, M., & Hakeda, Y. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4254 · Cited by 119
Yeo, L., Lom, H., Juarez, M., Snow, M., Buckley, C. D., Filer, A., Raza, K., & Scheel-Toellner, D. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204116 · Cited by 119
Signaling for survival and apoptosis in the immune system.
Mak, T. W., & Yeh, W. (2002) · Arthritis Research · doi:10.1186/ar569 · Cited by 138
Self-citationTranscriptional regulation of bone and joint remodeling by NFAT
Sitara, D., & Aliprantis, A. O. (2009) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00849.x · Cited by 124
Hofbauer, L. C. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410195 · Cited by 138
Roles of Wnt signals in bone resorption during physiological and pathological states
Maeda, K., Takahashi, N., & Kobayashi, Y. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0974-0 · Cited by 127
“Both RANKL- [10] and RANK-deficient mice [11] develop severe osteopetrosis with no osteoclasts in bone.”
BackgroundOsteoclast formation and resorption
Lerner, U. H. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00052-4 · Cited by 154
Fukada, S. Y., Silva, T. A., Garlet, G. P., Rosa, A. L., Silva, J. S., & Cunha, F. Q. (2008) · Oral Microbiology and Immunology · doi:10.1111/j.1399-302x.2008.00469.x · Cited by 129
“Moreover, an imbalance in RANK–RANKL–OPG levels has been observed in several other pathologies, such as osteoporosis, osteopetrosis, rheumatoid arthritis, periodontal diseases, and altered tooth eruption (5, 17, 35, 41, 44).”
Oyajobi, B. O., Anderson, D. M., Traianedes, K., Williams, P. J., Yoneda, T., & Mundy, G. R. (2001) · PubMed · Cited by 128
Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
Li, H., Gao, J., Gao, Y., Lin, N., Zheng, M., & Ye, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580605 · Cited by 124
Kwok, S., Cho, M., Park, M., Oh, H.-J., Park, J., Her, Y., Lee, S.-Y., Youn, J., Ju, J. H., Park, K. S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33390 · Cited by 129
Belibasakis, G. N., Bostancı, N., Hashim, A., Johansson, A. S., Aduse‐Opoku, J., Curtis, M. A., & Hughes, F. J. (2007) · Microbial Pathogenesis · doi:10.1016/j.micpath.2007.03.001 · Cited by 131
“These include Receptor Activator of NF-kB Ligand (RANKL), a surface-associated ligand expressed on hematopoietic bone marrow stromal cells and periosteal osteoblasts [13], as well as B and T lymphocytes [14].”
BackgroundGiuliani, N., Colla, S., & Rizzoli, V. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.03.015 · Cited by 128
“RANKL directly induces osteoclastogenesis together with M-CSF and inhibits osteoclast apoptosis by binding to its specific receptor (RANK) present on osteoclast progenitors and mature osteoclasts [15,16,18,19].”
BackgroundInfluentialSwanson, C., Lorentzon, M., Conaway, H. H., & Lerner, U. H. (2006) · Endocrinology · doi:10.1210/en.2005-0717 · Cited by 116
Death to the bad guys: Targeting cancer via Apo2L/TRAIL
Bouralexis, S., Findlay, D. M., & Evdokiou, A. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6060-0 · Cited by 136
Bone loss in inflammatory arthritis: mechanisms and treatment strategies
Walsh, N. C., & Gravallese, E. M. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000127824.42507.68 · Cited by 124
McLaughlin, F., Mackintosh, J., Hayes, B., McLaren, A., Uings, I., Salmon, P., Humphreys, J., Meldrum, E., & Farrow, S. N. (2002) · Bone · doi:10.1016/s8756-3282(02)00737-8 · Cited by 126
The immune system, bone and RANKL
Guerrini, M. M., & Takayanagi, H. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.003 · Cited by 129
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 122
Zauli, G., Rimondi, E., Nicolin, V., Melloni, E., Celeghini, C., & Secchiero, P. (2004) · Blood · doi:10.1182/blood-2004-03-1196 · Cited by 113
Role of DNA methylation in the regulation of the RANKL-OPG system in human bone
Delgado‐Calle, J., Sañudo, C., Fernández, A. F., García-Renedo, R. J., Fraga, M. F., & Riancho, J. A. (2012) · Epigenetics · doi:10.4161/epi.7.1.18753 · Cited by 122
“On the other hand, OPG (Osteoprotegerin, the product of the TNFRSF11B gene) protects bone from excessive resorption by binding to RANKL and thus avoiding its interaction with RANK.(4,5) In addition, recent findings suggest that OPG may function as a traffic regulator of RANKL, modulating its ability to reach the cell…”
BackgroundMellis, D. J., Itzstein, C., Helfrich, M. H., & Crockett, J. C. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0212 · Cited by 112
“…RANKL (Tnfsf11) in mice and presence of loss-of-function mutations in humans have been associated with osteoclast-poor osteopetrosis caused by lack of osteoclast formation in both mice and humans (Dougall et al. 1999, Hsu et al. 1999, Kong et al. 1999, Sobacchi et al. 2007, Guerrini et al. 2008).”
BackgroundLactoferrin reduces in vitro osteoclast differentiation and resorbing activity
Lorget, F., Clough, J., de Oliveira, M. C., Daury, M.-C., Sabokbar, A., & Offord, E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00849-5 · Cited by 126
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
Younes, A., & Kadin, M. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.037 · Cited by 127
Osteoimmunology in rheumatic diseases
Schett, G. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2571 · Cited by 115
“Both cell types inducibly express RANKL, which is an essential stimulating signal for osteoclastogenesis and is also involved in the activation of mature osteoclasts [3,17].”
BackgroundReceptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2
Kim, N.-S., Kim, H.-J., Koo, B.-K., Kwon, M.-C., Kim, Y.-W., Cho, Y., Yokota, Y., Penninger, J. M., & Kong, Y.-Y. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.1002-1013.2006 · Cited by 110
“RANKL-deficient mice exhibit severe osteopetrosis and tooth eruption failure due to a complete absence of osteoclasts (19).”
BackgroundMethodSelf-citationHarmsen, A., Kusser, K., Hartson, L., Tighe, M., Sunshine, M. J., Sedgwick, J. D., Choi, Y., Littman, D. R., & Randall, T. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.986 · Cited by 118
“Although LN and PP organogenesis and organization are absolutely dependent on the expression of LT , the cellular and molecular interactions involved in the organogenesis of PPs and various subsets of LNs still differ in their precise details and timing (5, 10, 11).”
BackgroundInfluentialRankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model
To, T. T., Witten, P. E., Renn, J., Bhattacharya, D., Huysseune, A., & Winkler, C. (2011) · Development · doi:10.1242/dev.071035 · Cited by 126
Amelioration of rat adjuvant‐induced arthritis by Met‐RANTES
Shahrara, S., Proudfoot, A. E. I., Woods, J. M., Ruth, J. H., Amin, M. A., Park, C. C., Haas, C. S., Pope, R. M., Haines, G. K., Zha, Y. Y., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21033 · Cited by 119
RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II
Hemingway, F., Taylor, R., Knowles, H. J., & Athanasou, N. A. (2010) · Bone · doi:10.1016/j.bone.2010.12.023 · Cited by 123
“In normal (canonical) osteoclastogenesis, MCSF (macrophage colony-stimulation factor) [4] and RANKL (receptor activator for nuclear factor κB ligand) are required for the differentiation of mononuclear phagocyte osteoclast precursors into fully functional, multinucleated osteoclasts [5,6].”
BackgroundHasegawa, T., Yoshimura, Y., Kikuiri, T., Yawaka, Y., Takeyama, S., Matsumoto, A., Oguchi, H., & Shirakawa, T. (2002) · Journal of Periodontal Research · doi:10.1034/j.1600-0765.2002.01603.x · Cited by 124
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
Schett, G., Stach, C., Zwerina, J., Voll, R., & Manger, B. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23951 · Cited by 112
Bacteria Induce Osteoclastogenesis via an Osteoblast-Independent Pathway
Jiang, Y., Mehta, C. K., Hsu, T.-Y., & Alsulaimani, F. F. (2002) · Infection and Immunity · doi:10.1128/iai.70.6.3143-3148.2002 · Cited by 115
“Activated T lymphocytes have been shown to express OPGL and contribute significantly to the regulation of systemic and local bone loss (14, 15).”
BackgroundLocal Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
Cawley, K. M., Bustamante-Gomez, N. C., Guha, A. G., MacLeod, R. S., Xiong, J., Gubrij, I., Liu, Y., Mulkey, R., Palmieri, M., Thostenson, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108052 · Cited by 114
“Receptor activator of nuclear factor κ B (NF-κ B) ligand (RANKL) is a member of the tumor necrosis factor (TNF) family and is essential for osteoclast differentiation, survival, and activity (Kong et al., 1999; Lacey et al., 1998).”
The role of miR‐29 family in disease
Horita, M., Farquharson, C., & Stephen, L. A. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29896 · Cited by 119
Yasui, T., Kadono, Y., Nakamura, M., Oshima, Y., Matsumoto, T., Masuda, H., Hirose, J., Omata, Y., Yasuda, H., Imamura, T., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.357 · Cited by 107
Patntirapong, S., Habibović, P., & Hauschka, P. V. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.062 · Cited by 119
The role of Snail in prostate cancer
Smith, B., & Odero-Marah, V. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.21687 · Cited by 113
Crotti, T. N., Dharmapatni, A. A. S. S. K., Alias, E., & Haynes, D. R. (2015) · Journal of Immunology Research · doi:10.1155/2015/281287 · Cited by 117
Cobourne, M. T., & Sharpe, P. T. (2012) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.66 · Cited by 133
Giant cells around bone biomaterials: Osteoclasts or multi-nucleated giant cells?
Miron, R. J., Zohdi, H., Fujioka‐Kobayashi, M., & Bosshardt, D. D. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.09.029 · Cited by 119
Organogenesis of peripheral lymphoid organs
Nishikawa, S., Honda, K., Vieira, P., & Yoshida, H. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00063.x · Cited by 119
Self-citationMbalaviele, G., Abu-Amer, Y., Meng, A., Jaiswal, R., Beck, S., Pittenger, M. F., Thiede, M. A., & Marshak, D. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.19.14388 · Cited by 114
Functions of the osteocyte network in the regulation of bone mass
Komori, T. (2013) · Cell and Tissue Research · doi:10.1007/s00441-012-1546-x · Cited by 111
“Further, IL-6 and IL-1 induce receptor activator of nuclear factor κ-B ligand (Rankl) expression, which is essential for osteoclastogenesis (Yasuda et al. 1998; Kong et al. 1999; O’Brien 2010).”
BackgroundEverts, V. E., de Vries, T. J., & Helfrich, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.05.004 · Cited by 122
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H., & Corey, E. (2001) · PubMed · Cited by 123
Self-citationNew Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?
Tat, S. K., Pelletier, J.-P., Velasco, C. R., Padrines, M., & Martel-Pelletier, J. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.29 · Cited by 112
Ahmad, S. F., Ansari, M. A., Zoheir, K. M. A., Bakheet, S. A., Korashy, H. M., Nadeem, A., Ashour, A. E., & Attia, S. M. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.01.008 · Cited by 112
The origins and roles of osteoclasts in bone development, homeostasis and repair
Yahara, Y., Nguyen, T., Ishikawa, K., Kamei, K., & Alman, B. A. (2022) · Development · doi:10.1242/dev.199908 · Cited by 104
Ikeda, T., Utsuyama, M., & Hirokawa, K. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1416 · Cited by 107
M cell-depletion blocks oral prion disease pathogenesis
Donaldson, D. S., Kobayashi, A., Ohno, H., Yagita, H., Williams, I. R., & Mabbott, N. A. (2012) · Mucosal Immunology · doi:10.1038/mi.2011.68 · Cited by 108
Coupling factors involved in preserving bone balance
Kim, B.-J., & Koh, J.-M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2981-y · Cited by 111
Camara, A., Cordeiro, O. G., Alloush, F., Sponsel, J., Chypre, M., Onder, L., Asano, K., Tanaka, M., Yagita, H., Ludewig, B., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.05.008 · Cited by 109
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis
Xu, S., Wang, Y., Lu, J., & Xu, J. (2011) · Rheumatology International · doi:10.1007/s00296-011-2175-5 · Cited by 114
“mice showed a decreased number of osteoclasts, increased bone mineral density (BMD), even osteoporosis [11].”
BackgroundYao, Z., Xing, L., Qin, C., Schwarz, E. M., & Boyce, B. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706415200 · Cited by 109
Molecular mechanisms of inflammatory bone damage: emerging targets for therapy
Herman, S., Krönke, G., & Schett, G. A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.04.001 · Cited by 122
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.